Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ziconotide acetate
Drug ID BADD_D02382
Description Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.[A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835]
Indications and Usage
Marketing Status Prescription; Discontinued
ATC Code N02BG08
DrugBank ID DB06283
KEGG ID D08686
MeSH ID C078452
PubChem ID 16129690
TTD Drug ID D01NLB
NDC Product Code 70720-720; 32861-0007; 70720-722; 70720-723
Synonyms ziconotide | CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2 | omega-conotoxin MVIIA | omega-conotoxin M VIIA | omega-conopeptide MVIIA | leconotide | SNX 111 | SNX-111 | omega-conotoxin MVIIA, Conus magus | Prialt
Chemical Information
Molecular Formula C102H172N36O32S7
CAS Registry Number 107452-89-1
SMILES CC1C(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(CS SCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)NC(C(=O)NCC(=O)NC(C (=O)N3)CO)C(C)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CCCNC(= N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Electrocardiogram abnormal13.14.05.001--Not Available
Fall12.01.08.002--
Fatigue08.01.01.002--
Gait disturbance17.02.05.016; 08.01.02.002--
Generalised tonic-clonic seizure17.12.01.002--Not Available
Hallucination19.10.02.002--
Hallucination, auditory19.10.02.003--Not Available
Hallucination, visual19.10.02.004--Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.002--
Incoherent19.10.03.006; 17.02.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Irritability19.04.02.013; 08.01.03.011--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Loss of consciousness17.02.04.004--Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Meningitis17.06.03.001; 11.01.03.001--
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages